EdgeMode Inc. (EDGM): Hey Laster, I appreciate your info but d...

Hey Laster, I appreciate your info but don't

lambchops · 2023-02-02T18:56:28.8600000Z

Hey Laster, I appreciate your info but don't really think anyone cares about FWAV anymore. LC FWAV

Play Episode

6min

Proactive - Interviews for investors

Atrato Partners on Social Housing REIT (SOHO): strategy, debt and dividend outlook

Atrato Partners, the newly appointed Investment Manager of Social Housing REIT (SOHO) talked with Proactive's Stephen Gunnion about the current state of the specialised supported housing sector and how the company is tackling key challenges within its portfolio. Fund manager Adrian D'Enrico was joined by Michael Carey and Natalie Markham, offering a comprehensive update on SOHO’s operational and financial performance. D'Enrico addressed common misconceptions about the sector, clarifying that it is not temporary or homeless accommodation, but instead provides long-term homes for adults with care needs. “A misconception as well is that specialised supported housing is a passive investment based on the long lease,” he explained, underlining the importance of resident occupancy and the operational real estate nature of the assets. Carey detailed the steps taken to resolve issues with Parasol and My Space Housing Solutions, including lease transfers to stronger providers, which are expected to improve rent collection. “We’ve collected 72% of the contracted amount so far with Westmoreland, and we’re confident we’ll meet our target,” he said. Markham reviewed the FY24 results, noting that while net tangible assets declined to £0.99 per share, rent collection stood at 93% and the company maintains strong debt metrics with an average maturity of 8.6 years and a 2.74% all-in cost. For more updates like this, head to Proactive's YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications so you never miss future content. #SocialHousing #REIT #AtratoPartners #SOHO #SpecialisedSupportedHousing #IncomeSecurity #RealEstateInvestment #DividendStocks #UKHousing #InvestorUpdate #PropertyPortfolio #ESGInvesting

Proactive - Interviews for investors

Digitalbox CEO James Carter on strong 2024 growth and 2025 outlook

Digitalbox PLC (AIM:DBOX) CEO James Carter takes Proactive's Stephen Gunnion through the company’s strong 2024 performance and its strategy heading into 2025. The company delivered a 31% increase in revenue during the year, with Carter describing it as “a good turnaround year.” He pointed to audience growth that outperformed broader news media trends, and revenue growth that exceeded global digital advertising market averages. Carter credited the success to the strength of Digitalbox’s brands and editorial teams, as well as the company’s in-house Graphene Ad Stack technology. “The editorial teams are really very well tuned into what their audiences want,” he said. Among standout performers were TV Guide, which achieved 90% traffic growth in Q4 following a move to a web app format, and The Tab, which benefited from social media asset integration. The Poke also saw a 22% increase in traffic following increased content investment. The company expanded its portfolio from six to eight brands in 2024, aiming to reach ten by the end of 2025. Looking ahead, Carter said 2025 is in line with expectations so far, and Digitalbox remains “cautiously optimistic” amid projected 10% growth in the digital ad market. Visit Proactive’s YouTube channel for more videos, and don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #Digitalbox #JamesCarter #MediaGrowth #DigitalAdvertising #TVGuide #TheTab #OnlineMedia #RevenueGrowth #AdTech #MediaBrands #InvestorUpdate #ProactiveInvestors

Proactive - Interviews for investors

Actinogen targets $20B Alzheimer’s market with Xanamem

Actinogen Medical Ltd Managing Director and CEO Dr Stephen Gourlay talked with Proactive at the AIM's Small and Midcap conference about the company’s lead asset, Xanamem, and its development in Alzheimer’s disease and depression. Dr Gourlay explained that Xanamem is an oral, once-a-day drug designed to modulate cortisol levels in the brain without interfering with the body’s essential stress response. “We’ve also shown some positive data, you know, phase two and depression as well, which is very exciting because that validates its mechanism,” he said. He outlined the commercial opportunity in both Alzheimer’s and depression. While depression is more prevalent, the Alzheimer's market offers larger potential revenue. He noted that current treatments either have side effects or provide only temporary cognitive improvement, whereas Xanamem could modify the disease course with a better safety profile. Dr Gourlay discussed Actinogen’s recent momentum, including positive results in a depression trial, a number of peer-reviewed publications, and the upcoming interim analysis from its Alzheimer’s trial in Australia and the US. He said, “The upside from a positive Alzheimer’s trial is completely massive… a multi-billion dollar asset.” The company is currently trading below the total investment into drug development, which Dr Gourlay described as a compelling investment case. #Actinogen #Xanamem #AlzheimersResearch #DepressionTreatment #BiotechStocks #ClinicalTrials #Neuroscience #PharmaInnovation #ASX #ProactiveInvestors

Proactive - Interviews for investors

AI translation tech: Straker CEO talks IBM partnership

Straker Ltd CEO Grant Straker talked with Proactive at AIM"S Small and Midcap Conference about how the company is leveraging artificial intelligence to reshape the global language services industry. Straker explained how the business evolved from early content management systems into a leading AI-powered translation platform over the last 15 years. The company focuses on blending machine learning with human expertise to deliver high-quality, cost-effective language services. A key milestone has been the integration of its platform by IBM, which now uses Straker’s technology for all its internal translations. “They’ve gone from a multi-vendor traditional model to just us,” Straker said, highlighting how the move has streamlined IBM’s operations while reducing costs. He also discussed the company's proprietary "Terry" language model and its innovative quality estimation* system. This tool evaluates translated content for accuracy, determining whether it needs human review—improving efficiency and boosting gross margins. Straker outlined a clear investor case, emphasizing three pillars: financial strength, innovation, and global distribution. The company is targeting revenues of AUD 45 million for the year, with no debt, AUD 12 million in cash, and annual R&D investment of AUD 7 million. With operations in ten countries and strategic alignment with IBM’s AI stack, Straker positioned the company as well-placed to scale quickly through operating leverage in AI. #AI #StrakerLtd #GrantStraker #LanguageTech #TranslationAI #IBMPartnership #ArtificialIntelligence #InvestorUpdate #MachineTranslation #TechStocks #ASXStocks #TerryModel #QualityEstimation #ProactiveInvestors #SmallCapASX

Followers	678
Posts	11361
Boards Moderated	1
Alias Born	02/20/2011

Volume:	-
Day Range:
Bid:	0.0026
Ask:	0.0026
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

EDGM Detailed Quote

Recent EDGM News

More EDGM News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent EDGM News

Go Ad-Free